Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: An open-label, randomised phase 3 trial

1. Motzer, R.J.
2. Porta, C.
3. Vogelzang, N.J.
4. Sternberg, C.N.
5. Szczylik, C.
6. Zolnierek, J.
7. Kollmannsberger, C.
8. Rha, S.Y.
9. Bjarnason, G.A.
10. Melichar, B.
11. De Giorgi, U.
12. Grünwald, V.
13. Davis, I.D.
14. Lee, J.-L.
15. Esteban, E.
16. Urbanowitz, G.
17. Cai, C.
18. Squires, M.
19. Marker, M.
20. Shi, M.M.
21. Escudier, B.